Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07156565 · ClinicalTrials.gov registry record · Phase 1

Actinium Therapy for Late-stage Aggressive Sarcomas

A Phase 1 study of Advanced Soft Tissue Sarcoma, sponsored by Ratio Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
6
Study locations

NCT07156565 is a Phase 1 study of Advanced Soft Tissue Sarcoma that is actively recruiting participants, run by Ratio Therapeutics. The registered enrollment target is 30 participants, below the 86-participant average among 6 other Advanced Soft Tissue Sarcoma trials with a reported enrollment target (65% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07156565, a Phase 1 study of Advanced Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Ratio Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
6
Study locations

Study Summary

The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests. * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests * Remain in long term follow-up for a period of four additional years

Conditions Studied

Advanced Soft Tissue Sarcoma

Interventions

  • DRUG [Ac 225]RTX-2358
  • DIAGNOSTIC_TEST [Cu64]LNTH-1363S

Study Locations (6)

California

  • UCLA - Los Angeles

Minnesota

  • Mayo Clinic - Rochester

New York

  • Memorial Sloane Kettering Cancer Center - New York

Ohio

  • Case Western - Cleveland

Texas

  • MD Anderson Cancer Center - Houston

Ontario

  • Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-11-12
Est. Completion 2032-01
Phase Phase 1

Sponsor

Ratio Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07156565

The ClinicalTrials.gov registry entry for NCT07156565 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 6 other Advanced Soft Tissue Sarcoma trials with a reported enrollment target (65% lower). The listed sponsor is Ratio Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which [Ac 225]RTX-2358 is the first listed.

NCT07156565 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Minnesota, New York.

Frequently Asked Questions

What is clinical trial NCT07156565 about?

NCT07156565 is a clinical study titled "Actinium Therapy for Late-stage Aggressive Sarcomas". The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in ...

What is the current status of trial NCT07156565?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-11-12. Estimated completion is 2032-01.

What conditions does trial NCT07156565 study?

This clinical trial studies the following conditions: Advanced Soft Tissue Sarcoma.

What interventions are being tested in trial NCT07156565?

The interventions under investigation include: [Ac 225]RTX-2358 (DRUG), [Cu64]LNTH-1363S (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07156565?

This trial is sponsored by Ratio Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07156565 being conducted?

This trial has 6 study locations across California, Minnesota, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Soft Tissue Sarcoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.